Regulatory Green Light Sends AstraZeneca Pharma Up 3%-Imfinzi Gets Major Boost
By HDFC Sky | Published at: Jul 2, 2025 02:41 PM IST
Mumbai, July 2, 2025 – AstraZeneca Pharma India Ltd (NSE: ASTRAZEN) stock price rose more than 3% to ₹9,199.00 in the afternoon on Wednesday after the CDSCO approved its oncology blockbuster Imfinzi (Durvalumab) for a new use in first-line treatment of advanced or recurrent endometrial cancer. It will be used with carboplatin and paclitaxel, followed by maintenance therapy with Imfinzi and Olaparib.
AstraZeneca India is still doing very well, with its stock price going up almost 40% in the previous year and more than 23% in the past six months. The shares are currently trading close to a critical resistance level of ₹9,200. Investors will now be looking at trends in adoption, impending earnings, and any other regulatory milestones relating to Imfinzi.
Expanded Approval Details
AstraZeneca received the nod to import and market Durvalumab Solution for Infusion (120 mg/2.4 ml and 500 mg/10 ml) in India for first-line treatment of adults with primary advanced or recurrent endometrial cancer, in combination with carboplatin and paclitaxel. This is followed by maintenance therapy with Durvalumab and Olaparib for mismatch repair proficient (pMMR) endometrial cancers.
This regulatory approval adds to AstraZeneca’s strong performance in the fourth quarter of FY25, when net profit climbed 47.7% year over year to ₹58.2 crore and revenue rose 25.4% to ₹480.4 crore, thanks to higher demand for cancer drugs and better market penetration. Imfinzi could greatly expand AstraZeneca’s oncology portfolio in India. It has already been approved for endometrial cancer in other countries, and it got fast-tracked approval in the U.S. after a key DUO-E trial showed a 58% lower risk of disease progression or death.
Key Stock Metrics (as of 12:31 pm IST)
| Metric | Value |
|---|---|
| Last Traded Price (NSE) | ₹9,199.00 |
| % Change | +3.38% |
| Day’s High / Low | ₹9,188 / ₹8,870 |
| VWAP | ₹9,060.44 |
| 52-Week High / Low | ₹10,691 / ₹6,150 |
| Market Cap | ₹22,695 crore |
| Adjusted P/E | 91.93 |
| Free Float Market Cap | ₹5,582 crore |
| Deliverable Quantity Ratio | 34.79% |
Regulatory Context
The approval was disclosed under Regulation 30 of the SEBI (LODR) Regulations, 2015, marking a key development for the company’s oncology pipeline in India.
About the Company
AstraZeneca Pharma India Ltd, listed on NSE and BSE since May 2001, operates in the pharmaceutical sector and is a part of the NIFTY 500 index. The company focuses on therapies in oncology, cardiovascular, renal, metabolic, and respiratory areas, with a growing portfolio in India’s specialty drugs segment.
The stock remains in focus with sustained investor interest, especially after its regulatory advancement in the high-potential oncology segment.
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
